Gilead Sciences, Inc. (NASDAQ:GILD) Receives Consensus Recommendation of “Buy” from Analysts
Gilead Sciences, Inc. (NASDAQ:GILD) has received a consensus recommendation of “Buy” from the twenty-six research firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $82.95.
GILD has been the topic of a number of analyst reports. Wells Fargo & Co raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their target price for the company from $68.00 to $88.00 in a research note on Monday, July 15th. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Morgan Stanley set a $82.00 target price on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Monday, July 15th. Cantor Fitzgerald set a $88.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Evercore ISI reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Friday, May 17th.
In other news, EVP Brett A. Pletcher sold 7,200 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total transaction of $468,504.00. Following the sale, the executive vice president now directly owns 34,398 shares of the company’s stock, valued at $2,238,277.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Brett A. Pletcher sold 608 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $64.35, for a total transaction of $39,124.80. Following the sale, the executive vice president now directly owns 27,198 shares in the company, valued at $1,750,191.30. The disclosure for this sale can be found here. Insiders have sold 13,624 shares of company stock worth $907,479 over the last ninety days. Insiders own 0.20% of the company’s stock.
NASDAQ GILD traded down $1.71 on Friday, reaching $62.51. The company’s stock had a trading volume of 5,445,326 shares, compared to its average volume of 6,092,799. The firm has a market cap of $81.22 billion, a PE ratio of 10.16, a price-to-earnings-growth ratio of 3.04 and a beta of 1.16. The business has a 50-day moving average price of $65.54 and a 200 day moving average price of $65.74. Gilead Sciences has a 52 week low of $60.32 and a 52 week high of $79.61. The company has a current ratio of 3.76, a quick ratio of 3.67 and a debt-to-equity ratio of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.14. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.54 billion. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The firm’s revenue for the quarter was down 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.91 earnings per share. Analysts anticipate that Gilead Sciences will post 6.65 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, September 12th. This represents a $2.52 annualized dividend and a yield of 4.03%. Gilead Sciences’s dividend payout ratio is 40.98%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.